The World Health Organisation said on Friday that results from an interim analysis of the Guinea Phase III efficacy vaccine trial showed that the vaccine used in the Guinea study, VSV-EBOV, is highly effective against Ebola. The independent body of international experts, the Data and Safety Monitoring Board, which conducted the review, therefore advised that...
Read the rest of the story on The Punch News
Added July 31, 2015
from The Punch News